Notes on the design of bioequivalence study: Delamanid

Notes on the design of bioequivalence studies with products invited to be submitted to the WHO Prequalification Team – Medicines (PQTm) are issued to aid manufacturers with the development of their product dossier. Deviations from the approach suggested below can be considered acceptable if justified by sound scientific evidence.


Below, additional specific guidance is provided on the invited immediate release products containing delamanid.

Pharmacokinetics of delamanid

In different studies, peak delamanid concentrations have been observed at ~ 4-8 h and around 4 hours in patients.

The oral bioavailability of delamanid improves when administered with a standard meal by about 2.7-fold compared to fasting conditions. After a 200 mg dose administered after a standard meal, the mean AUC∞, AUCt and Cmax were 2.9-, 3.0- and 3.4-fold greater, respectively, compared to that observed under fasted conditions. Administration after a high fat meal produced a > 4-fold increase on AUC vs. the fasting state with a 400 mg dose. Delamanid plasma exposure increases less than proportionally with increasing dose.

Across studies, the available data suggests that delamanid is eliminated from plasma with a t½ of 30 to 38 hours. Delamanid does not undergo chiral inter-conversion in vivo.

Intra-subject variability was moderate (27% to 39%)

Guidance for the design of bioequivalence studies:

Taking into account the pharmacokinetic properties of delamanid the following guidance with regard to the study design should be taken into account:

Design: A cross-over design is recommended.

Dose: As the EoI includes only the 50 mg strength of delamanid tablet, this strength (1 x 50 mg) should be tested versus the comparator, assuming the bioanalytical methodology is sufficient (see below).

For studies involving a 50 mg conventional-release IR Test product, the Test and Comparator products should be administered in the bioequivalence study with the same posology e.g., administration with 240 mL of water. For a 50 mg dispersible tablet, the Test dispersible product should be administered as it will be labeled to be administered in the clinical setting e.g., disperse in a small volume (for example 50 mL) of water and administer, followed by a rinse with a second small volume of water (for example 50 mL), while the Comparator should be administered with 240 mL water as per normal.
**Fasting/fed:** The bioequivalence study should be conducted in the fed state with a normal breakfast (500 – 600 Kcal), or a high-fat high-calorie meal.

**Subjects:** Healthy adult subjects should be included in the bioequivalence study. It is not necessary to include patients.

**Sample size:** Information currently available in the reference product public assessment report indicates that the intra-subject variability for delamanid is around 27 to 39%, with highest values in primarily outpatient conditions and therefore with more variable food intake. These data may facilitate the calculation of a sufficient sample size for the bioequivalence study.

**Washout:** A wash out period 2 weeks seems to be adequate for a drug with a half-life of 38 hours.

**Blood sampling:** The blood sampling should be intensive between 2 and 8 hours after administration. It is not necessary to take samples after 72 hours. For example, blood samples might be taken at pre-dose, 1.00, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 9.00, 10.00, 12.00, 24.00, 48.00 and 72.00 h after drug administration.

**Analytical considerations:** Information currently available indicates that it is possible to measure delamanid in human plasma using LC-MS/MS analytical methodology. The bioanalytical method should be sufficiently sensitive to detect concentrations that are 5% of the C\text{max} in most profiles of each formulation (test or comparator).

**Parent or metabolite data for assessment of bioequivalence:** The parent drug is considered to best reflect the biopharmaceutical quality of the product. The data for the parent compound should be used to assess the bioequivalence of delamanid.

**Statistical considerations:** The data for delamanid should meet the following bioequivalence standards in a single-dose cross-over design study:

- The 90% confidence interval of the relative mean $\text{AUC}_{0-72h}$ of the test to reference product should be within 80-125%.

- The 90% confidence interval of the relative mean $\text{C}_{\text{max}}$ of the test to reference product should be within 80-125%.

Information currently available in the reference product public assessment report indicates that the comparator product is not a highly variable drug product.